<DOC>
	<DOCNO>NCT01170221</DOCNO>
	<brief_summary>This randomize , double-blind , double dummy , multicenter Phase 3 study oral TR-701 FA 200 mg daily 6 day versus oral ZyvoxÂ® ( linezolid ) 600 mg every 12 hour 10 day treatment ABSSSI adult . Approximately 75 100 site globally participate study . Patients ABSSSI cause suspected documented gram positive pathogen ( ) baseline randomize 1:1 study treatment</brief_summary>
	<brief_title>TR-701 FA vs. Linezolid Treatment Acute Bacterial Skin Skin Structure Infections .</brief_title>
	<detailed_description>The primary objective determine noninferiority early clinical response rate 6 day oral TR-701 FA compare 10-day oral linezolid treatment 48-72 Hour Visit ITT analysis set patient ABSSSI .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Torezolid phosphate</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Torezolid</mesh_term>
	<criteria>Patients systemic sign infection diagnose acute bacterial skin skin structure infection ( ABSSSI ) Diagnosed Cellulitis/ erysipelas , major cutaneous abscess , wound infection Uncomplicated skin infection Severe sepsis septic shock ABSSSI solely due gramnegative pathogen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>ABSSSI</keyword>
	<keyword>Tedizolid Phosphate</keyword>
	<keyword>TR-701</keyword>
	<keyword>Acute Bacterial Skin Skin Structure Infections</keyword>
</DOC>